适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 481
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
招募中
1 期
A study to learn about the taste of Vericiguat given in liquid form in healthy male participants aged 18 to 45 yearsCTIS2023-508447-52-00Bayer AG20
招募中
1 期
A study in healthy subjects investigating the safety, tolerability and concentrations of FE 999301 after single and multiple dosesInflammatory Gastrointestinal DiseaseMedDRA version: 20.0Level: HLGTClassification code: 10017969Term: Gastrointestinal inflammatory conditions Class: 10017947CTIS2023-507882-24-00Ferring Pharmaceuticals A/S48
进行中（未招募）
1 期
To Study the Safety and Pharmacokinetics of BLYG8824A in Patients with Locally Advanced or Metastatic Colorectal Cancersocally Advanced or Metastatic Colorectal Cancers (mCRC)MedDRA version: 27.0Level: PTClassification code: 10052358Term: Colorectal cancer metastatic Class: 100000004864CTIS2023-503409-12-00Genentech Inc.58
进行中（未招募）
1 期
A study to learn more about how BAY3283142 moves into, through, and out of the body of healthy participants when taken together with atazanavir and to assess the proportion of BAY3283142 that reaches the blood when taken by mouth.MedDRA version: 20.1Level: LLTClassification code: 10054109Term: Non-proliferative diabetic retinopathy Class: 10015919MedDRA version: 23.1Level: PTClassification code: 10064848Term: Chronic kidney disease Class: 100000004857Chronic kidney diseaseCTIS2024-510856-11-00Bayer AG15
招募中
1 期
An exploratory study to investigate the effect of FE 999302 when given together with follitropin delta during controlled ovarian stimulatioInfertility in women undergoing assisted reproductive technologies (ART)CTIS2023-507630-25-00Ferring Pharmaceuticals A/S600